Parameter | n | Out-of-field PSMA-positive findings | PSMA pattern |
RT to prostate and seminal vesicles with pelvic LNs | 73 | ||
Major impact on RT planning outside CTV | 12 (16.5%) | ||
Extension of prostate CTV | 1 (1.5%) | 1 T out | N0M0 |
Extension of consensus pelvic LN CTV | 2 (2.5%) | 2 N out | N1M0 |
Extension of both prostate CTV and consensus pelvic LN CTV | 2 (2.5%) | 2 T out + N out | N1M0 |
Oligometastasis-directed SBRT (≤5 M1a or M1b) | 3 (4%) | 2 M1b | N0M1b |
1 M1a + M1b | N1M1aM1b | ||
Oligometastasis-directed SBRT + extension of prostate CTV | 1 (1.5%) | 1 T out + M1b | N1M1a |
RT futile because of polymetastatic or visceral disease | 3 (4%) | 1 M1a | N1M1a |
1 N out + M1a | N1M1a | ||
1 M1b + M1c | N1M1bM1c | ||
RT to prostate and seminal vesicles without pelvic LNs | 66 | ||
Major impact on RT planning outside CTV | 21 (32%) | ||
Addition of whole pelvic LN CTV | 13 (19.5%) | 13 N out | N1M0 |
Extension of prostate CTV | 1 (1.5%) | 1 T out | N0M0 |
Extension of both prostate and consensus pelvic LN CTV | 1 (1.5%) | 1 T out + N out | N1M0 |
Oligometastasis-directed SBRT (≤5 M1a or M1b) | 3 (4.5%) | 2 M1b | N0M1b |
1 M1a + M1b | N1M1aM1b | ||
Oligometastasis-directed SBRT + extension of prostate CTV | 1 (1.5%) | 1 T out + M1a | N1M1a |
RT futile because of polymetastatic or visceral disease | 3 (4.5%) | 1 M1a | N1M1a |
1 N out + M1a | N1M1a | ||
1 M1b + M1c | N1M1bM1c |
SBRT = stereotactic body RT.